16427-44-4

Basic information

• Product Name: METHANESULFONIC ACID 2-METHOXYETHYL ESTER
• Synonyms: 2-METHOXYETHYL METHANESULFONATE;METHANESULFONIC ACID 2-METHOXYETHYL ESTER;2-Methoxymethyl Methansulfonate
• CAS NO: 16427-44-4
• Molecular Formula: C₄H₁₀O₄S
• Molecular Weight: 154.18
• Mol File: 16427-44-4.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 126 °C / 12mmHg
• Flash Point: 110.4°C
• Appearance: /
• Density: 1.25
• Vapor Pressure: 0.0215mmHg at 25°C
• Refractive Index: 1.4300-1.4340
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHANESULFONIC ACID 2-METHOXYETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: METHANESULFONIC ACID 2-METHOXYETHYL ESTER(16427-44-4)
• EPA Substance Registry System: METHANESULFONIC ACID 2-METHOXYETHYL ESTER(16427-44-4)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 16427-44-4(Hazardous Substances Data)

Usage

Description

METHANESULFONIC ACID 2-METHOXYETHYL ESTER, also known as 2-Methoxymethyl Methansulfonate, is a chemical compound with the formula C4H10O4S. It is an ester derived from methanesulfonic acid and 2-methoxyethanol. METHANESULFONIC ACID 2-METHOXYETHYL ESTER is known for its reactivity and is commonly utilized in various chemical reactions and processes.

Uses

Used in Polymer Industry:
METHANESULFONIC ACID 2-METHOXYETHYL ESTER is used as a reagent for the ring-opening polymerization of lactide. It facilitates the formation of polylactic acid (PLA), a biodegradable and biocompatible polymer with applications in packaging, agriculture, and medical devices.
Used in Pharmaceutical Industry:
METHANESULFONIC ACID 2-METHOXYETHYL ESTER is used as an intermediate in the synthesis of acetylcholine receptor ligands. These ligands are essential for the development of drugs targeting neurological disorders, such as Alzheimer's disease and myasthenia gravis, due to their role in the regulation of neurotransmission.

InChI:InChI=1/C4H10O4S/c1-7-3-4-8-9(2,5)6/h3-4H2,1-2H3

Upstream product

• 109-86-4 2-methoxy-ethanol 
• 124-63-0 methanesulfonyl chloride 
• 616-47-7 1-methyl-1H-imidazole 

Downstream Products

• 627-43-0 fluoro-1, methoxy-2 ethane 
• 65275-38-9 β-Methoxyethyl(phenyl)selenid 
• 109-86-4 2-methoxy-ethanol 
• 169616-09-5 dimethyl 3,4-bis-(2-methoxyethoxy)-1-benzylpyrrole-2,5-dicarboxylate 
• 484679-02-9 N,N-Bis(2-(2-methoxyethoxy)ethyl)benzene amine 
• 625119-89-3 2-methoxy-4-(2-methoxyethoxy)-1-nitrobenzene 
• 303197-30-0 3'-O-methoxyethyladenosine 
• 1062491-29-5 C₁₆H₂₅N₅O₆ 
• 1062491-27-3 C₁₆H₂₅N₅O₆ 
• 168427-74-5 2'-O-(2-methoxyethyl)adenosine 
• 256224-02-9 3'-O-methoxyethyl-2,6-diaminopurine riboside 
• 847647-19-2 C₁₆H₂₆N₆O₆ 
• 256224-13-2 2'-O-(2-methoxyethyl)-2,6-diaminopurine riboside 
• 1079402-29-1 2-[2-chloro-5-(2-methoxyethoxy)-phenyl]-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane 

Relevant articles and documents

Squaraines as Fluoro-Chromogenic Probes for Thiol-Containing Compounds and Their Application to the Detection of Biorelevant Thiols

A highly selective colorimetric chemodosimeter for thiol-containing compounds in aqueous solutions is reported. The design protocol makes use of a highly specific reaction between thiols and the electrophilic four-membered ring of highly colored, fluoresc

Functional magnetic mesoporous silica microparticles capped with an azo-derivative: A promising colon drug delivery device

Magnetic micro-sized mesoporous silica particles were used for the preparation of a gated material able to release an entrapped cargo in the presence of an azo-reducing agent and, to some extent, at acidic pH. The magnetic mesoporous microparticles were loaded with safranin O and the external surface was functionalized with an azo derivative 1 (bearing a carbamate linkage) yielding solid S1. Aqueous suspensions of S1 at pH 7.4 showed negligible safranin O release due to the presence of the bulky azo derivative attached onto the external surface of the inorganic scaffold. However, in the presence of sodium dithionite (azoreductive agent), a remarkable safranin O delivery was observed. At acidic pH, a certain safranin O release from S1 was also found. The pH-triggered safranin O delivery was ascribed to the acid-induced hydrolysis of the carbamate moiety that linked the bulky azo derivatives onto the mesoporous inorganic magnetic support. The controlled release behavior of S1 was also tested using a model that simulated the gastro intestinal tract.

Isolation of highly pure erlotinib hydrochloride by recrystallization after nucleophilic substitution of an impurity with piperazine

Optimized synthesis and purification of erlotinib hydrochloride (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazoline-4-amine hydrochloride) were studied. Highly polar piperazine was used in a nucleophilic substitution reaction with the chlorinated intermediate byproduct N-(3-ethynylphenyl)-6(2- chloroethoxy)-7-(2-methoxyethoxy)quinazolin-4-amine hydrochloride. As a result, N-(3-ethynylphenyl)-6(2-chloroethoxy)-7-(2-methoxyethoxy)quinazolin-4-amine hydrochloride was completely transformed to N-(3-ethynylphenyl)-6(2- piperzinoethoxy)-7-(2-methoxyethoxy)quinazolin-4-amine hydrochloride. The polarity of N-(3-ethynylphenyl)-6(2-piperzinoethoxy)-7-(2-methoxyethoxy) quinazolin-4-amine hydrochloride was changed, and its molecule was enlarged. It was easy to remove this larger, more polar, compound by recrystallization. Highly pure erlotinib hydrochloride was obtained with low impurity content (99.9 %.

SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF

The present invention relates to a silicon phthalocyanine complex, the preparation method and the medicinal application thereof. The present invention particularly relates to a silicon phthalocyanine complex of formula (I), the preparation method thereof and a pharmaceutical composition comprising the same, as well as the use thereof as a photosensitizer, in particular the use in the treatment of cancers, wherein each substituent in formula (I) is the same as defined in the description.

Erlotinid hydrochloride method for the preparation of key intermediate

The invention discloses a preparation method of an erlotinib hydrochloride key intermediate 4-chloro-6,7-di(2-methoxyethoxy)quinazoline, which comprises the following steps: reacting the raw material ethyl 3,4-dihydroxybenzoate with ethyl 2-methoxysulfonate, nitrating, reducing, cyclizing and chlorinating to obtain the key intermediate 4-chloro-6,7-di(2-methoxyethoxy)quinazoline. The method has the advantages of mild reaction conditions, low cost, high purity and high total yield (up to 74.8%), and can easily implement industrial production.